Ficerafusp Alfa, Pembrolizumab, and Stereotactic Body Radiotherapy (SBRT) for Head and Neck Squamous Cell Carcinoma (HNSCC)

NCT07552558 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

NOT_YET_RECRUITING

Status

45

Enrollment

OTHER

Sponsor class

Conditions

Head and Neck Squamous Cell Carcinoma
HPV-Negative Squamous Cell Carcinoma

Interventions

RADIATION: Hypofractionated Stereotactic Body Radiotherapy (SBRT)
BIOLOGICAL: Pembrolizumab
DRUG: Ficerafusp alfa

Sponsor

Washington University School of Medicine

Collaborators

[object Object]